AUM Biosciences awarded 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year from Frost & Sullivan

SINGAPORE, April 9, 2019 /PRNewswire/ -- AUM Biosciences has been honored with the 2019 Asia-Pacific Biotech  Entrepreneurial Company of the Year Award from Frost & Sullivan.

Vandana Iyer, Senior Research Analyst, Health & Wellness, TechVision, Frost & Sullivan noted that AUM Biosciences' unique 'Asia to Global' strategy, combined with biomarker-driven precision medicine plans and digitization trials, is ideally poised to address growing industry needs for designing faster and more affordable treatment strategies distinctly for the Asian landscape.

These include the company's integration of 3 key elements in its quest of targeted cancer therapeutics: developing affordable small molecule therapies, adopting "No Biomarker-No Drug" mandate and leveraging digitization for smart data access that improves the patient management journey in a personalized manner.

Frost & Sullivan firmly believes that AUM's drug development strategies have the power to lead a long-overdue paradigm shift in the Asian biotech landscape by facilitating the development of affordable treatment options and enabling improved quality of life for cancer patients.

"Amidst this backdrop, the company's lead MNK inhibitor candidate, AUM001, demonstrates an impressive safety profile and can potentially optimize the current treatment strategies for chronic myeloid leukemia and multiple solid tumors with significant unmet medical needs. AUM's unparalleled, Asia-focused drug development plans are set to enable disruptive biotech transformations in the global small molecule industry," she added.

AUM Biosciences also uniquely addresses the main concerns of the Asian biotech landscape related to treatment availability and affordability by facilitating the development of Asia-focused, affordable treatment strategies that are likely to transform the future of biomarker-based, digital precision medicine approaches.

Frost & Sullivan recognizes that AUM's comprehensive biomarker-based and trial digitization plans are likely to enable significant disruptions within the existing pharma and biotech landscape by enabling the development of precision therapies for the Asia-Pacific region. The company's affordable small molecule therapies of Asian origin will also facilitate improved disease management across the world.

"We are proud to receive this award. AUM is committed towards implementing a Holistic Approach of developing affordable cancer drugs from Asia to Global. This recognition makes our commitment even stronger," said AUM Biosciences CEO, Mr. Vishal Doshi

The recipients of the annual Frost & Sullivan Asia-Pacific Best Practice Awards were identified based on in-depth research conducted by Frost & Sullivan's analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends. The short-listed companies were evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused, Singapore HQ biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, we aim to create value for patients, physicians and our partners by harnessing the power of precision medicine, and digital health. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of cancers prevalent in Asians but has the potential to address global market.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. 

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies. 


Melissa Tan

Haslinda Sarabaini                           

Corporate Communications – Asia Pacific

AUM Biosciences

P: +65 6890 0926

P: +6568086034

F: +65 6890 0999




Related Links :

Look out for further updates on our Facebook fan page!

Related Articles

  • 【新冠肺炎】員工怕「中招」拒上班 管理層無法說服結果......

    疫情嚴重影響到各大企業的運作,如果業務性質許可,企業能安排員工在家工作(Work From Home)當然最好,但是部分行業難以實行......

  • 【人才管理】欣賞員工唔一定要用錢嘅! 專家建議5個方法一樣得


  • 【人才管理】真金助員工渡難關!Facebook宣布向員工派發獎金$7700元

    新冠肺炎擴散全球,各國的經濟受到不同程度的打擊。企業面減虧蝕、停業甚至倒閉風險,打工仔則面臨減薪、失業的壓力。根據美國有線電視新聞網(CNN) 報導,科技巨頭Facebook宣布向4萬5千名員工發放1,000美元的補助金(約7,766港元)。

  • 【企業管理】流動網絡普及 企業貪快貪方便蒙受損失


  • 【新冠肺炎】公務員逐步復工 專家︰企業是否跟隨考慮幾個因素


  • 【新冠肺炎】確診新冠肺炎前有症狀仍上班 網民:社畜病毒威力太強大


  • 【網民職場Talk】下屬奉旨幫上司執手尾?打工仔列慘痛經歷


  • 【職場熱話】18區最痛苦的返工地點!觀塘熱到變蒸爐?


  • 【網民職場Talk】大學Third Hon畢業 連累失面試機會?

    大學生近日陸續完成課程,開始踏上求職之路。若在大學取得一級榮譽(First Hon),可能會為CV加分,但在取得三級榮譽(Third Hon)的話,又會否影響僱主聘請意欲呢?有Third Hon畢業生遲遲未找到工作,在社交專頁《奴工處》投稿,了解Third Hon是否真的影響求職。

  • 【政府工略】政府統計處請統計助理 月薪$20,035 點先做到?